Provided by Tiger Trade Technology Pte. Ltd.

Ligand Pharmaceuticals

281.72
+1.540.55%
Post-market: 281.720.00000.00%19:30 EDT
Volume:197.41K
Turnover:55.78M
Market Cap:5.62B
PE:29.01
High:287.90
Open:284.22
Low:278.28
Close:280.18
52wk High:326.63
52wk Low:158.13
Shares:19.94M
Float Shares:19.35M
Volume Ratio:1.06
T/O Rate:1.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):9.71
EPS(LYR):6.13
ROE:21.96%
ROA:3.99%
PB:5.80
PE(LYR):45.96

Loading ...

Ligand Pharmaceuticals director Jason Haas reports sale of 6,461 common shares worth $1.65 million

Reuters
·
Jun 16

Pelthos Therapeutics director Todd C. Davis buys USD 999,994 of common stock

Reuters
·
Jun 16

Ligand Pharma director Jason Aryeh disposes of 5,000 common shares worth $1.25 million

Reuters
·
Jun 13

Ligand Pharma director John L. LaMattina disposes of 4,591 common shares worth $1.15 million

Reuters
·
Jun 13

Ligand to host investor day webcast for shareholders

Reuters
·
Jun 10

Ligand Pharmaceuticals stockholders approve restated 2002 stock incentive plan at annual meeting

Reuters
·
Jun 10

Is Ligand Pharmaceuticals (LGND) Still Undervalued After Its Strong Recent Share Price Momentum

Simply Wall St.
·
Jun 07

Analysts Are Bullish on Top Healthcare Stocks: Ligand Pharma (LGND), Tenaya Therapeutics (TNYA)

TIPRANKS
·
Jun 04

Ligand CLO, Secretary Andrew Reardon sells USD 1.11 million in common shares

Reuters
·
Jun 03

BofA Securities Adjusts Ligand Pharmaceuticals Price Target to $266 From $263

MT Newswires Live
·
May 28

Ligand Pharma (LGND) Receives a Buy from Bank of America Securities

TIPRANKS
·
May 28

Ligand Pharmaceuticals to join Goldman Sachs Global Healthcare Conference fireside chat

Reuters
·
May 28

Xoma downgraded to Hold from Buy at Benchmark

TIPRANKS
·
May 22

Ligand Pharmaceuticals Bets Big on Royalty Growth

TIPRANKS
·
May 20

Is It Too Late To Consider Ligand Pharmaceuticals (LGND) After Its 97% One-Year Surge?

Simply Wall St.
·
May 19

XOMA Royalty amends merger agreement with Ligand Pharmaceuticals

TIPRANKS
·
May 18

Ligand amends XOMA Royalty merger agreement to add new holding company entity

Reuters
·
May 18

Ligand director John W. Kozarich sells USD 572,598 common shares

Reuters
·
May 15

RBC Capital Keeps Their Buy Rating on Ligand Pharma (LGND)

TIPRANKS
·
May 12

Ligand Pharmaceuticals’ Earnings Call Signals Scaled Royalty Push

TIPRANKS
·
May 12